DNA and DNA metabolic enzymes

DNA and DNA metabolic enzymes represent a broad class of therapeutic targets essential for the storage, replication, and repair of genetic information (National Human Genome Research Institute). DNA itself serves as a direct target for various cytotoxic agents, such as alkylating agents and intercalators, which covalently modify or disrupt its structure to prevent cellular division (StatPearls). DNA metabolic enzymes, including DNA polymerases, topoisomerases, and helicases, facilitate the complex processes of unwinding, copying, and re-sealing the double helix (UniProt). In oncology, these targets are frequently exploited because rapidly dividing cancer cells have a heightened dependency on efficient DNA replication and repair mechanisms (Nature Reviews Cancer). Beyond cancer, these enzymes are critical targets for antiviral and antibacterial therapies, where drugs selectively inhibit pathogen-specific polymerases or gyrases (PubMed). However, because these processes are also fundamental to healthy cell survival, drugs targeting DNA and its metabolic machinery often exhibit significant systemic toxicities, such as bone marrow suppression and gastrointestinal distress (American Cancer Society).

Other names

Deoxyribonucleic acidDNA replication machineryDNA repair enzymesNucleic acid targetsDNA synthesis enzymes

Drugs targeting this group act through various mechanisms including direct DNA alkylation and cross-linking (StatPearls), intercalation between base pairs to disrupt helical structure (PubChem), competitive inhibition of DNA polymerases (UniProt), stabilization of cleavage complexes by topoisomerase inhibitors (Nature Reviews Cancer), and the blockade of DNA repair pathways such as those mediated by poly(ADP-ribose) polymerase (PARP) (NIH).